相似文献
1
Should women be offered cholesterol lowering drugs to prevent cardiovascular disease? Yes.
BMJ. 2007 May 12;334(7601):982. doi: 10.1136/bmj.39202.399942.AD.
2
Should women be offered cholesterol lowering drugs to prevent cardiovascular disease? No.
BMJ. 2007 May 12;334(7601):983. doi: 10.1136/bmj.39202.397488.AD.
3
Primary prevention cardiovascular disease: better than drugs.
Arch Intern Med. 2010 Nov 8;170(20):1860-1; author reply 1861. doi: 10.1001/archinternmed.2010.402.
4
Is there evidence for the evidence-based guidelines for cardiovascular disease prevention in women?
Gend Med. 2006 Mar;3(1):5-12. doi: 10.1016/s1550-8579(06)80189-0.
5
Editorial: collecting new external evidence for cholesterol management.
Curr Opin Endocrinol Diabetes Obes. 2016 Apr;23(2):121-3. doi: 10.1097/MED.0000000000000244.
6
Cholesterol lowering with statin drugs: evidence in women.
JAMA. 1997 Nov 26;278(20):1660-1.
7
Update on statins and other lipid-lowering drugs.
Geriatr Nurs. 2001 Sep-Oct;22(5):276-7. doi: 10.1067/mgn.2001.119477.
8
Lipid-Lowering Therapies: Risks in Women and Evidence-Based Options.
Tex Heart Inst J. 2018 Aug 1;45(4):238-239. doi: 10.14503/THIJ-18-6691. eCollection 2018 Aug.
9
IMPROVE-IT clinical implications. Should the "high-intensity cholesterol-lowering therapy" strategy replace the "high-intensity statin therapy"?
Atherosclerosis. 2015 May;240(1):161-2. doi: 10.1016/j.atherosclerosis.2015.03.002. Epub 2015 Mar 10.
10
The New 2018 Cholesterol Guidelines.
Circulation. 2019 Jun 18;139(25):2805-2808. doi: 10.1161/CIRCULATIONAHA.118.038629. Epub 2018 Nov 10.
引用本文的文献
1
Sex differences in cardiologic medication provision for adults with coronary heart disease: an analysis of health claims data from 2018 to 2020 in Saxony-Anhalt, Germany.
BMC Health Serv Res. 2024 Mar 6;24(1):288. doi: 10.1186/s12913-024-10727-4.
2
Hiding unhealthy heart outcomes in a low-fat diet trial: the Women's Health Initiative Randomized Controlled Dietary Modification Trial finds that postmenopausal women with established coronary heart disease were at increased risk of an adverse outcome if they consumed a low-fat 'heart-healthy' diet.
Open Heart. 2021 Jul;8(2). doi: 10.1136/openhrt-2021-001680.
3
Cardiovascular disease and primary ovarian insufficiency.
Semin Reprod Med. 2011 Jul;29(4):328-41. doi: 10.1055/s-0031-1280918. Epub 2011 Oct 3.
4
Response by sex to statin plus ezetimibe or statin monotherapy: a pooled analysis of 22,231 hyperlipidemic patients.
Lipids Health Dis. 2011 Aug 22;10:146. doi: 10.1186/1476-511X-10-146.
5
Benefit of intensive statin therapy in women: results from PROVE IT-TIMI 22.
Circ Cardiovasc Qual Outcomes. 2011 May;4(3):328-36. doi: 10.1161/CIRCOUTCOMES.110.957720. Epub 2011 Apr 12.
6
Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials.
Circulation. 2010 Mar 9;121(9):1069-77. doi: 10.1161/CIRCULATIONAHA.109.906479. Epub 2010 Feb 22.
本文引用的文献
1
Are lipid-lowering guidelines evidence-based?
Lancet. 2007 Jan 20;369(9557):168-9. doi: 10.1016/S0140-6736(07)60084-1.
2
AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute.
Circulation. 2006 May 16;113(19):2363-72. doi: 10.1161/CIRCULATIONAHA.106.174516.
3
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
Lancet. 2005 Oct 8;366(9493):1267-78. doi: 10.1016/S0140-6736(05)67394-1. Epub 2005 Sep 27.
4
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
Circulation. 2004 Jul 13;110(2):227-39. doi: 10.1161/01.CIR.0000133317.49796.0E.
5
European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice.
Eur Heart J. 2003 Sep;24(17):1601-10. doi: 10.1016/s0195-668x(03)00347-6.
6
Lifetime risk of coronary heart disease by cholesterol levels at selected ages.
Arch Intern Med. 2003 Sep 8;163(16):1966-72. doi: 10.1001/archinte.163.16.1966.
7
34th Bethesda Conference: Task force #1--Identification of coronary heart disease risk: is there a detection gap?
J Am Coll Cardiol. 2003 Jun 4;41(11):1863-74. doi: 10.1016/s0735-1097(03)00358-9.
8
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.
Lancet. 2003 Apr 5;361(9364):1149-58. doi: 10.1016/S0140-6736(03)12948-0.
9
10
Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project.
Circulation. 2000 Oct 17;102(16):1893-900. doi: 10.1161/01.cir.102.16.1893.
Zotero 插件